Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

1642TiP - ENSURE: Dendritic cell therapy (MesoPher) in combination with extended-pleurectomy/decortication after chemotherapy in subjects with resectable mesothelioma: A feasibility study

Date

10 Sep 2022

Session

Poster session 06

Topics

Tumour Site

Mesothelioma

Presenters

Luca Cantini

Citation

Annals of Oncology (2022) 33 (suppl_7): S743-S749. 10.1016/annonc/annonc1076

Authors

L. Cantini1, M.V. Dietz1, R.A. Belderbos1, R. Cornelissen1, D.W. Dumoulin1, M. Vink1, K. Bezemer1, A.W. Langerak2, J. von der Thüsen3, E.A.F. Mahtab4, L.P.W.M. Maat4, R. Stadhouders1, R. Hendriks1, M. Willemsen1, J.G. Aerts1

Author affiliations

  • 1 Department Of Pulmonary Medicine, Erasmus MC, 3000 CA - Rotterdam/NL
  • 2 Department Of Immunology, Erasmus MC, 3000 CA - Rotterdam/NL
  • 3 Department Of Pathology, Grow School For Oncology And Developmental Biology, Erasmus MC - Erasmus University Rotterdam, 3000 CA - Rotterdam/NL
  • 4 3department Of Cardiothoracic Surgery, Erasmus MC, 3000 CA - Rotterdam/NL
More

Abstract 1642TiP

Background

Malignant pleural mesothelioma (MPM) is an uncommon but aggressive neoplasm with low survival rates. For patients with early stage resectable MPM the role of radical surgery remains controversial and multimodal treatment might improve patient prognosis. Dendritic cell therapy (DCT) with Mesopher proved to be safe and yielded promising results in patients with MPM, with single agent radiological activity, representing the rationale for a combined (neo)adjuvant approach with extended pleurectomy/decortication (eP/D) surgery.

Trial design

This open label, single center, phase 1 study will evaluate the feasibility of DCT with Mesopher performed before and after eP/D in patients with resectable epithelioid MPM. Safety and immunological effects of (neo)adjuvant DCT will also be determined. Sixteen adult patients diagnosed with resectable epithelioid MPM will be enrolled following first-line chemotherapy. Before standard-of-care chemotherapy, a leukapheresis will be performed from which monocytes will be isolated and used for further differentiation into DCs. Hereafter, DCs will be loaded with allogeneic MPM tumor cell line lysate (Pheralys) and maturated using the Jonuleit cytokine cocktail. The subsequently formulated drug product (Mesopher) will be re-injected 4 weeks after completing chemotherapy, 2 times every other week. Four weeks after the first injection with DCT, patients will undergo eP/D surgery followed by three bi-weekly injections with DCT, starting 4 weeks after surgery. In total, five DC vaccinations will be administered. Tumor material will be collected before starting neo-adjuvant DCT and at time of surgery. Tumor-specific immune activation will be investigated using both tumor material and peripheral blood samples prior and post DCT with flow cytometry, imaging mass cytometry, and T-cell receptor repertoire analysis. The trial is active at the Erasmus MC, Rotterdam (NL), enrolling patients since January 2022.

Clinical trial identification

NCT05304208.

Editorial acknowledgement

Legal entity responsible for the study

Erasmus MC.

Funding

Erasmus MC.

Disclosure

L. Cantini: Financial Interests, Personal and Institutional, Research Grant: ESMO. R. Cornelissen: Financial Interests, Personal, Invited Speaker: BMS, Roche, Pfizer, Boehringer Ingelheim, Novartis; Financial Interests, Personal, Advisory Role: Roche, MSD, Boehringer Ingelheim. D.W. Dumoulin: Financial Interests, Personal, Invited Speaker: BMS, Roche, Pfizer, Novartis. J.G. Aerts: Financial Interests, Personal and Institutional, Research Grant: Amphera, Eli Lilly, Roche; Financial Interests, Personal, Ownership Interest: Amphera; Financial Interests, Personal, Advisory Board: Amphera, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Takeda, Bayer, AstraZeneca, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.